Calcium for Osteoporosis

Calcium supplements are not a treatment for osteoporosis on their own. They raise bone mineral density (BMD) by about 0.7-1.8%, a gain that does not keep growing after the first year (Tai 2015), and a 2026 meta-analysis of 69 trials, mostly in adults not at high fracture risk and not on osteoporosis drugs, found calcium alone made little to no difference to the risk of any fracture (risk ratio 0.91, 95% CI 0.81 to 1.01); evidence in high-risk people was limited (Massé 2026).

The picture is more positive when calcium is combined with vitamin D in people at high risk. A Cochrane review found a small reduction in hip fractures, about 9 fewer per 1,000 people a year in institutions but only 1 fewer per 1,000 in the community (Avenell 2014). Calcium still matters as part of care: guidelines pair adequate calcium and vitamin D intake with fracture-preventing medication (LeBoff 2022), and bisphosphonates are the first-line treatment for postmenopausal osteoporosis (Qaseem 2023).

Calcium is the main mineral in bone. After menopause, falling estrogen reduces calcium absorption and increases calcium loss through the urine and from bone, and bone resorption outpaces formation for about 5 years (NIH ODS 2026). When calcium and vitamin D are low, parathyroid hormone rises and pulls calcium from the skeleton.

Supplements can reverse that. In an 18-month trial in 3,270 women with a mean age of 84, calcium with vitamin D lowered parathyroid hormone by 44% and raised 25-hydroxyvitamin D by 162% in a subset of 142 women; in 56 women, hip bone density rose 2.7% with treatment and fell 4.6% with placebo (Chapuy 1992).

In most people, the bone effect is small and stops growing. Across 51 trials of calcium supplements in over 12,000 people aged over 50, BMD rose 0.7-1.8%, and the gain at later time points was similar to the gain at one year; the authors judged it unlikely to produce a clinically significant fall in fractures (Tai 2015).

Higher doses did not help more in that analysis: increases were similar for doses of 1,000 mg or more versus less, and whether people started with dietary intakes below or above 800 mg a day (Tai 2015). Bone density is also a stand-in, and fracture trials are what count.

The goal is a total daily intake, not a supplement dose. The recommended intake is 1,200 mg a day for women over 50 and for everyone over 70, and 1,000 mg for men aged 51-70; the upper limit for adults over 50 is 2,000 mg a day from all sources (NIH ODS 2026). The fracture trials used 1,000-1,200 mg a day of supplemental calcium, often with 400-800 IU of vitamin D (Jackson 2006; Prince 2006; Chapuy 1992).

Label reality: calcium carbonate is 40% calcium by weight and is best taken with food; calcium citrate is 21% calcium and can be taken without food. Absorption is highest at doses of 500 mg or less, so splitting the dose helps: the body absorbs about 36% of a 300 mg dose but 28% of a 1,000 mg dose. Supplement Facts panels list the elemental calcium, so no conversion is needed (NIH ODS 2026).

A 2015 systematic review of 26 trials found calcium supplements, with or without vitamin D, reduced total fractures (RR 0.89, 95% CI 0.81 to 0.96) and, borderline, vertebral fractures (RR 0.86, 95% CI 0.74 to 1.00) but not hip or forearm fractures; results were similar with and without vitamin D. The published data were skewed in calcium's favour, and in the four trials at lowest risk of bias (44,505 people) there was no effect on fracture at any site (Bolland 2015).

The 2026 meta-analysis, which excluded people already on osteoporosis drugs and mostly included people not at high fracture risk, rated calcium alone as having little to no effect on any fracture (11 trials, 9,067 people; RR 0.91, 95% CI 0.81 to 1.01; moderate certainty). In a 5-year trial of 1,200 mg a day in 1,460 women over 70, fractures did not fall overall (HR 0.87, 95% CI 0.67 to 1.12), but in the 57% who took at least 80% of their tablets they fell from 15.4% to 10.2% (HR 0.66), a non-randomised comparison (Massé 2026; Prince 2006).

In 3,270 women with a mean age of 84, 1.2 g of calcium with 800 IU of vitamin D for 18 months cut hip fractures by 43% (P = 0.043) and non-vertebral fractures by 32% (Chapuy 1992). The Cochrane review pooled 9 trials (49,853 people) and found a small hip fracture reduction (RR 0.84, 95% CI 0.74 to 0.96), with the largest absolute benefit in people living in institutions (Avenell 2014). A 2019 meta-analysis of 6 large trials using 1,000-1,200 mg calcium with 400-800 IU vitamin D found a 16% lower hip fracture risk (Yao 2019), and a 2016 National Osteoporosis Foundation analysis reported 30% (Weaver 2016). The 2026 meta-analysis, however, found combined supplements lowered the risk of any fracture only slightly (15 trials, 51,126 people; RR 0.91, 95% CI 0.84 to 0.99), an effect the authors judged too small to be clinically meaningful (Massé 2026).

In healthy community-dwelling women the results are weaker. The Women's Health Initiative gave 36,282 postmenopausal women 1,000 mg calcium with 400 IU vitamin D for an average of 7 years: hip density was 1.06% higher than with placebo, but hip fracture was not significantly reduced (HR 0.88, 95% CI 0.72 to 1.08) (Jackson 2006). A 2017 meta-analysis of 33 trials in community-dwelling adults over 50 found no link between calcium, vitamin D or both and fewer fractures (Zhao 2017).

The US Preventive Services Task Force recommends against daily calcium of 1,000 mg or less with vitamin D of 400 IU or less to prevent first fractures in healthy postmenopausal women living in the community, and finds the evidence for higher doses insufficient. That recommendation does not apply to people with diagnosed osteoporosis, a previous fracture or vitamin D deficiency (USPSTF 2018). For them, guidelines treat adequate calcium and vitamin D as one part of fracture prevention, with medication, weight-bearing and resistance exercise, no smoking, limited alcohol and fall prevention (LeBoff 2022).

Missing: a large trial of calcium alone in people with diagnosed osteoporosis, and evidence on whether supplements add anything for people whose diet already reaches the recommended intake. An older 2007 meta-analysis found a 12% fracture reduction that grew to 24% in trials with high adherence (Tang 2007), but later reviews with more trials found smaller or no effects.

Kidney stones rose 17% with calcium plus vitamin D in the Women's Health Initiative (HR 1.17, 95% CI 1.02 to 1.34) (Jackson 2006), and the Task Force found adequate evidence that combined supplements increase kidney stones (USPSTF 2018), although two later systematic reviews, one in more than 8,000 adults with osteoporosis, found no such link (NIH ODS 2026). The Cochrane review also found small increases in gastrointestinal symptoms and renal disease (RR 1.16), and mild high blood calcium was more common with vitamin D, with or without calcium (RR 2.28) (Avenell 2014). Constipation affected 13.4% of women on calcium vs 9.1% on placebo in a 5-year trial (Prince 2006); carbonate causes more gas, bloating and constipation than citrate (NIH ODS 2026).

Heart risk is debated. A 2010 meta-analysis found calcium supplements taken without vitamin D increased heart attacks (HR 1.31, 95% CI 1.02 to 1.67) (Bolland 2010), while a 2023 meta-analysis of 12 trials found no link with heart attack, stroke or death (Sim 2023). After 22 years of follow-up in the Women's Health Initiative, deaths from cardiovascular disease were 6% higher and cancer deaths 7% lower with calcium plus vitamin D, with no change in overall mortality, in a post hoc analysis (Thomson 2024). An expert panel concluded intakes within the upper limit are safe from a cardiovascular standpoint (NIH ODS 2026).

Calcium binds several medicines in the gut. Alendronate's label says calcium supplements interfere with its absorption and that patients should wait at least half an hour after the tablet before any other oral medicine; the same label says low blood calcium must be corrected before starting, and tells patients to take supplemental calcium and vitamin D if their dietary intake is inadequate (FDA). Calcium carbonate interferes with levothyroxine, which should be taken at least 4 hours apart; quinolone antibiotics should be taken 2 hours before or after calcium; dolutegravir 2 hours before or 6 hours after; and long-term lithium can cause high blood calcium, a risk calcium supplements may add to (NIH ODS 2026).